Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake
This trial has been completed.
|Condition||coronary artery disease|
|Start date||August 2012|
|End date||January 2017|
|Trial size||28 participants|
|Trial identifier||NCT01690884, 120477|
The investigators are trying to determine if a single dose of Ticagrelor will increase delivery of intraarterially-infused adenosine into the forearm interstitium, consistent with adenosine reuptake blockade.
|Endpoint classification||pharmacodynamics study|
|Intervention model||parallel assignment|
|Masking||single blind (subject)|
Interstitial levels of adenosine
time frame: After each dose of intrabrachial adenosine
All participants from 18 years up to 65 years old.
Inclusion Criteria: 1. Subjects will be healthy volunteers, without significant pulmonary, cardiovascular gastrointestinal, hematological or renal diseases 2. Not taking any regular medications 3. Able to provide signed consent prior to study participation. Exclusion Criteria: 1. History of asthma 2. Pregnancy 3. Exposure to an investigational drug in the last 2 months. 4. Known hypersensitivity to study medications
|Official title||Ticagrelor and Adenosine Uptake. Phase II Study Comparing the Effects of Ticagrelor vs Dipyridamole on Adenosine Uptake|
|Principal investigator||Italo Biaggioni, MD|
|Description||The investigators will compare adenosine interstitial levels using a parallel design study with three groups of subjects. Forearm interstitial adenosine levels will be measured at baseline and after intrabrachial infusion of adenosine at two doses. Subjects will then randomly receive Ticagrelor 180 mg, Dipyridamole 200 mg, or placebo. Two hours later the investigators will repeat the dialysate collections at baseline and after adenosine infusions.|
Call for more information